LRMR Company Profile and Key Details

LRMR has shown weak momentum, losing -1.54% over the past week and -23.81% over the past quarter, though year-to-date performance is down -16.01%. Short-term trend indicators are mixed aligned (SMA20 73.98%, SMA50 69.26%, SMA200 70.01%). The stock’s 14-day RSI is 79.91 (overbought), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading 10.8% below its high and over 269.57% above its low. Average 10-day trading volume of 22.07 million shares is significantly above the 3-month average of 3.60 million, indicating heightened recent market interest.

Larimar Therapeutics, Inc. has 85.59 million shares outstanding. The public float is 43.14 million shares, elevated short interest at 11.18% of float. This equals 6.37 million shares. The short ratio is 6.11 days. Institutional investors hold 84.67% of the float. Insiders own 1.07%. Flynn James E holds 7.32 million shares, Hamilton Thomas Edward has 564.80 thousand shares and BEN-MAIMON CAROLE has 266.83 thousand shares.

Larimar Therapeutics, Inc. generated EPS of -$1.93 over the past year. Five-year average earnings growth is 50.78%. Wall Street analysts project EPS growth of -0.62% annually over the next five years. The latest quarter delivered EPS of -$0.61. The next quarter is forecast at -$0.49. Next year's EPS is expected at -$39.69. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $7.00. The high target offers 336.97% upside. The low target suggests 17.65% downside. The mean target is $17.64. This offers 196.47% upside. Larimar Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 56.19%. The prior quarter beat by -12.77%. Over the last six quarters, Apple has recorded several small beats. These include 6.25% in August 07, 2024.

Larimar Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.46. This means the shares are trading above this model’s fair value.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) closed at $5.95 USD, gaining $2.26 (61.25%) from the previous close of $3.69. The stock is currently mid-range between its 52-week high and low $1.61 and $6.42. With a market capitalization of about $509.26 million, Larimar Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.00). Key stats such as the average daily volume over the past year has been around 1.20 million shares, trading with heavier-than-usual volume. Headquartered in Bala Cynwyd, PA, Larimar Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carole S. Ben-Maimon, the company employs approximately 65 people and listed since June 19, 2014. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Larimar Therapeutics, Inc. trades at a P/E ratio of -3.61, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.43 trading at moderately above to book value. The P/FCF stands at -5.38, also above market averages.

Our AI price prediction model suggests that Larimar Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -48.24%, with price expected at $3.08 by March 10, 2026, within a range of $2.86 to $3.29 3-Month Outlook: Projected fall of -45.21%, reaching $3.26 by May 25, 2026, with a range of $2.85 to $3.56. 1-Year Outlook: Projected loss of -2.35%, with price at $5.81 by February 24, 2027, within a range of $0.00 to $6.70.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) shares are down -16.01% year-to-date hovering near 52-week lows. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Larimar Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.61. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $16.19, suggesting 172.1% upside. Our AI forecast model points to short-term weakness (-48.24% over two weeks), a medium-term fall (-45.21% over three months), and a longer-term loss (-2.35% over one year), with expected trading ranges indicating moderate volatility.